BMY·NYSE·US
Bristol Myers Squibb
Bristol Myers Squibb is a global biopharmaceutical company that develops and sells prescription medicines, with major franchises in oncology, hematology, immunology, and cardiovascular disease. Its revenue is driven primarily by branded pharmaceutical product sales rather than medical devices, software, or tools.
Recent Activity
Updated Oct 31, 2026
–BioNTech and Bristol Myers Squibb reported encouraging global Phase 2 data for pumitamig plus docetaxel in advanced non-small cell lung cancer after progression on immunotherapy plus chemotherapy, with responses seen in squamous and non-squamous disease across PD-L1 expression levels.
–Pathos AI announced a collaboration with Bristol Myers Squibb and Tempus AI to develop artificial intelligence tools for drug development.
–Bristol Myers Squibb was named alongside Novartis as having announced fatal events in an autoimmune cell therapy trial, before Artiva disclosed similar events and said it would stop its autoimmune cell therapy work.
Past updates are part of the Pro plan.
Thematic Position
Relationship Groups
Relationship details are part of the Pro plan.
Recent Discoveries
Recent discoveries are part of the Pro plan.
Ended Relationships
Management Perspective on Regulatory & Geopolitical Developments
Disclosed customers above 10% of revenue
Related Events
1 event · Related events are part of the Pro plan.